QUALITY MANAGEMENT OF VETERINARY PRODUCTS OF UKRAINIAN ENTERPRISES ON ENTERING THE FOREIGN MARKET

Mohylna L.M.
Candidate of Economic Sciences, Sumy National Agrarian University

The article analyses development of a definition “quality”, which underwent changes and is reflected in texts of international standards. Quality is in some measure, a philosophical category which was studied as far back as the times of Aristotle.

Quality requirements were constantly changed. Production conditions were also changed that, in turn, coordinate and stimulate development of quality management.

International trade of veterinary medicines requires an appropriate standardization and certification of production and at the country level – certain strategy of moving toward the European Union. In order to secure production of high-quality veterinary medicines it is necessary to introduce and maintain standards and requirements of Good Manufacturing Practice, which is unified for all producers, time- and experience-proven and provides tailored manufacturing that answers requirements of regulatory documents. Good Manufacturing Practice (GMP) – is a collection of rules concerning organization of production and quality control, which are an element of the system of its providing.

It should be noted that in any case for ensuring development, production reconstruction and making it consistent with international rules, national biofactories need additional market outlets. Perspectives that can be related to entrance into markets of Asia are achievable and probable; moreover, it is also possible to consider entrance to the European market. But it is not an easy task. Indeed, the most of Ukrainian producers who export their production incredulously assess a possibility of development of markets of Western Europe and other developed countries where it is necessary to prove that a veterinary preparation not only made in the proper way (in accordance with GMP) but also analysed in a laboratory (GLP) and clinic (GCP), after all, there is a complicated system of access to Reimbursement List (list of medicinal products), which value is compensated by insurance companies.